Newsroom

Here you will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

Media Enquiries - CSL Limited
Jemimah Pentland
Head of Communications, Asia Pacific
Phone: +613 9389 3473
Mobile: +61 412 635 483
jemimah.pentland@csl.com.au

RSS Subscribe to our RSS feed

01/12/2016
CSL Commits to New Phase I Clinical Trials in Australia
CSL Commits to New Phase I Clinical Trials in Australia

CSL has today announced that it has progressed three new therapies into first-in-human studies in Australia. In keeping with the Company’s objective to expand its research and development pipeline and pursue a diverse portfolio, all three products are new generation, high-tech medicines based on targeted monoclonal antibody technologies.

 
More.

16/11/2016
CSL Behring Presents Positive Results from CSL112 Phase 2b Trial

CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.

 
More.

14/11/2016
AFSTYLA® (rFVIII-SC) - CHMP recommendation
Afstyla CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for CSL Behring’s AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.
 
More.

14/10/2016
New Debt Facilities
Maturity Profile of Debt by Facility 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 13 October 2016 it closed a new USD550 million private placement in the US. The private placement was foreshadowed in CSL’s full year announcement in August 2016.
 
More.

11/10/2016
Australian Scientists awarded $2.5m in support of ground-breaking research into Alzheimer’s Disease and Leukaemia
CSL Fellows Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.
 
More.

30/08/2016
FDA Accepts CSL Behring’s BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
FDA Accepts CSL Behring BLA CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks.
 
More.

17/08/2016
Full Year Result 2016
CSL Delivers Another Strong Performance

FY Results 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016.
 
More.

17/08/2016
CSL Announces Changes to the Board
Changes To The Board CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016.
 
More.

04/07/2016
CSL to Support new Biopharmaceutical Training Centre at UQ
Biopharmaceutical Training Centre at UQ CSL is pleased to announce it will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland.
 
More.

10/06/2016
CSL Behring is 2016 ‘Victorian Manufacturer of the Year’
Manufacturer Of The Year Thumbnail CSL Behring’s Australian facility was last night awarded ‘2016 Victorian Manufacturer of the Year’ in the Large Business category at the Victorian Manufacturing Hall of Fame Awards.
 
More.

06/06/2016
Seqirus donates vaccines to Fiji to alleviate increase in influenza
Fiji Donation Thumbnail CSL’s subsidiary, Seqirus, today announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza.
 
More.

01/06/2016
CSL Centenary Fellowships: Call for Applications
CSL Fellowships Applications CSL is now calling for applications for the two inaugural fellowships to be awarded in late 2016, for commencement on 1 January 2017.
 
More.

26/05/2016
AFSTYLA® (rFVIII-Single Chain) – FDA approval
Afstyla CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.
 
More.

24/05/2016
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
Holly Springs CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
 
More.

12/05/2016
IDELVION® (rFIX-FP) - European Commission Approval
Idelvion CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
 
More.

25/04/2016
CSL Celebrates 100 Years of Operation
Celebrating 100 Years Australia’s largest and most successful biotechnology company, CSL, will officially celebrate 100 years of operation on 25th April 2016.
 
More.

14/04/2016
CSL Announces $25 million Centenary Fellowship Program
Fellowships Announcement CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.
 
More.

07/03/2016
Expanded Bio21 to house global research hub
bio21 Expansion The University of Melbourne’s internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL’s Global Research and Translational Medicine Hub.
 
More.

07/03/2016
IDELVION® (rFIX-FP) – FDA approval
Idelvion CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.
 
More.

29/02/2016
IDELVION® (rFIX-FP) - CHMP recommendation
Idelvion CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.
 
More.

16/02/2016
CSL Appoints New Director
Megan Clark Announcement CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.
 
More.

16/02/2016
Half Year Result 2016
CSL Delivers Exceptional Performance

Half Year Report 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2.
 
More.

>> Prior Archived Newsroom


 

© 2016 CSL Limited